APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncolytic Virus Therapy

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Selected research

Market Outlook & Growth Opportunities

Global Oncolytic Virus Therapy Market Outlook and Growth Opportunities 2026

25 December 2025190 pages

Choose your research edition.

Industry ResearchOncolytic Virus Therapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncolytic Virus Therapy Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Oncolytic Virus Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncolytic Virus Therapy Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncolytic Virus Therapy Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.

North America and Europe are the main markets, each accounting for about 40% of the market.

Read the full market overview

This report provides an overview of the global Oncolytic Virus Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncolytic Virus Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncolytic Virus Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oncolytic Virus Therapy market.

Oncolytic Virus Therapy Segment by Company

Amgen

Oncolytics Biotech

Viralytics

Transgene SA

Oncolys BioPharma

Targovax

PsiOxus Therapeutics

SillaJen Biotherapeutics

Sorrento Therapeutics

Lokon Pharma

Genelux Corporation

Vyriad

TILT Biotherapeutics

Cold Genesys

Oncolytic Virus Therapy Segment by Type

HSV-based Oncolytic Viruses

Adenoviruses-based Oncolytic Viruses

Vaccinia Virus-based Oncolytic Viruses

Vesicular Stomatitis Virus-based Oncolytic Viruses

Newcastle Disease Virus-based Oncolytic Viruses

Oncolytic Virus Therapy Segment by Application

Melanoma

Prostate Cancer

Breast Cancer

Ovarian Cancer

Others

Oncolytic Virus Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncolytic Virus Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oncolytic Virus Therapy key companies, revenue, market share, and recent developments.

3. To split the Oncolytic Virus Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oncolytic Virus Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncolytic Virus Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Oncolytic Virus Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncolytic Virus Therapy industry.

Chapter 3: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oncolytic Virus Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oncolytic Virus Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncolytic Virus Therapy Industry Trends Table 2. Oncolytic Virus Therapy Industry Drivers Table 3. Oncolytic Virus Therapy Industry Opportunities and Challenges Table 4. Oncolytic Virus Therapy Industry Restraints Table 5. Global Oncolytic Virus Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncolytic Virus Therapy Revenue Share by Company (2021-2026) Table 7. Global Oncolytic Virus Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oncolytic Virus Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Oncolytic Virus Therapy Company, Product Type & Application Table 10. Global Oncolytic Virus Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oncolytic Virus Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of HSV-based Oncolytic Viruses Table 15. Significant Companies of Adenoviruses-based Oncolytic Viruses Table 16. Significant Companies of Vaccinia Virus-based Oncolytic Viruses Table 17. Significant Companies of Vesicular Stomatitis Virus-based Oncolytic Viruses Table 18. Significant Companies of Newcastle Disease Virus-based Oncolytic Viruses Table 19. Global Oncolytic Virus Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Oncolytic Virus Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Oncolytic Virus Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Oncolytic Virus Therapy Sales Value Share by Type (2021-2026) Table 23. Global Oncolytic Virus Therapy Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Melanoma Table 25. Significant Companies of Prostate Cancer Table 26. Significant Companies of Breast Cancer Table 27. Significant Companies of Ovarian Cancer Table 28. Significant Companies of Others Table 29. Global Oncolytic Virus Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oncolytic Virus Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Oncolytic Virus Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Oncolytic Virus Therapy Sales Value Share by Application (2021-2026) Table 33. Global Oncolytic Virus Therapy Sales Value Share by Application (2027-2032) Table 34. Global Oncolytic Virus Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oncolytic Virus Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Oncolytic Virus Therapy Sales Value Share by Region (2021-2026) Table 37. Global Oncolytic Virus Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Oncolytic Virus Therapy Sales Value Share by Region (2027-2032) Table 39. Global Oncolytic Virus Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Oncolytic Virus Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Oncolytic Virus Therapy Sales Value Market Share by Country (2021-2026) Table 42. Global Oncolytic Virus Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Oncolytic Virus Therapy Sales Value Market Share by Country (2027-2032) Table 44. Amgen Company Information Table 45. Amgen Business Overview Table 46. Amgen Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Amgen Oncolytic Virus Therapy Product Portfolio Table 48. Amgen Recent Development Table 49. Oncolytics Biotech Company Information Table 50. Oncolytics Biotech Business Overview Table 51. Oncolytics Biotech Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio Table 53. Oncolytics Biotech Recent Development Table 54. Viralytics Company Information Table 55. Viralytics Business Overview Table 56. Viralytics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Viralytics Oncolytic Virus Therapy Product Portfolio Table 58. Viralytics Recent Development Table 59. Transgene SA Company Information Table 60. Transgene SA Business Overview Table 61. Transgene SA Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Transgene SA Oncolytic Virus Therapy Product Portfolio Table 63. Transgene SA Recent Development Table 64. Oncolys BioPharma Company Information Table 65. Oncolys BioPharma Business Overview Table 66. Oncolys BioPharma Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio Table 68. Oncolys BioPharma Recent Development Table 69. Targovax Company Information Table 70. Targovax Business Overview Table 71. Targovax Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Targovax Oncolytic Virus Therapy Product Portfolio Table 73. Targovax Recent Development Table 74. PsiOxus Therapeutics Company Information Table 75. PsiOxus Therapeutics Business Overview Table 76. PsiOxus Therapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio Table 78. PsiOxus Therapeutics Recent Development Table 79. SillaJen Biotherapeutics Company Information Table 80. SillaJen Biotherapeutics Business Overview Table 81. SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio Table 83. SillaJen Biotherapeutics Recent Development Table 84. Sorrento Therapeutics Company Information Table 85. Sorrento Therapeutics Business Overview Table 86. Sorrento Therapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio Table 88. Sorrento Therapeutics Recent Development Table 89. Lokon Pharma Company Information Table 90. Lokon Pharma Business Overview Table 91. Lokon Pharma Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Lokon Pharma Oncolytic Virus Therapy Product Portfolio Table 93. Lokon Pharma Recent Development Table 94. Genelux Corporation Company Information Table 95. Genelux Corporation Business Overview Table 96. Genelux Corporation Oncolytic Virus Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Genelux Corporation Oncolytic Virus Therapy Product Portfolio Table 98. Genelux Corporation Recent Development Table 99. Vyriad Company Information Table 100. Vyriad Business Overview Table 101. Vyriad Oncolytic Virus Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Vyriad Oncolytic Virus Therapy Product Portfolio Table 103. Vyriad Recent Development Table 104. TILT Biotherapeutics Company Information Table 105. TILT Biotherapeutics Business Overview Table 106. TILT Biotherapeutics Oncolytic Virus Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio Table 108. TILT Biotherapeutics Recent Development Table 109. Cold Genesys Company Information Table 110. Cold Genesys Business Overview Table 111. Cold Genesys Oncolytic Virus Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Cold Genesys Oncolytic Virus Therapy Product Portfolio Table 113. Cold Genesys Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Oncolytic Virus Therapy Product Image Figure 2. Global Oncolytic Virus Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncolytic Virus Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncolytic Virus Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. HSV-based Oncolytic Viruses Image Figure 8. Adenoviruses-based Oncolytic Viruses Image Figure 9. Vaccinia Virus-based Oncolytic Viruses Image Figure 10. Vesicular Stomatitis Virus-based Oncolytic Viruses Image Figure 11. Newcastle Disease Virus-based Oncolytic Viruses Image Figure 12. Global Oncolytic Virus Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Oncolytic Virus Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Oncolytic Virus Therapy Sales Value Share by Type (2021-2032) Figure 15. Melanoma Image Figure 16. Prostate Cancer Image Figure 17. Breast Cancer Image Figure 18. Ovarian Cancer Image Figure 19. Others Image Figure 20. Global Oncolytic Virus Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Oncolytic Virus Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Oncolytic Virus Therapy Sales Value Share by Application (2021-2032) Figure 23. Global Oncolytic Virus Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Oncolytic Virus Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Oncolytic Virus Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. North America Oncolytic Virus Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Oncolytic Virus Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Oncolytic Virus Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Oncolytic Virus Therapy Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Oncolytic Virus Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Oncolytic Virus Therapy Sales Value (2021-2032) & (US$ Million) Figure 32. South America Oncolytic Virus Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Oncolytic Virus Therapy Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Oncolytic Virus Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Vaccinia Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses
Applications
  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Others
Companies covered
  • Amgen
  • Oncolytics Biotech
  • Viralytics
  • Transgene SA
  • Oncolys BioPharma
  • Targovax
  • PsiOxus Therapeutics
  • SillaJen Biotherapeutics
  • Sorrento Therapeutics
  • Lokon Pharma
  • Genelux Corporation
  • Vyriad
  • TILT Biotherapeutics
  • Cold Genesys

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncolytic Virus Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncolytic Virus Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oncolytic Virus Therapy Market Dynamics
  1. 2.1 Oncolytic Virus Therapy Industry Trends
  2. 2.2 Oncolytic Virus Therapy Industry Drivers
  3. 2.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
  4. 2.4 Oncolytic Virus Therapy Industry Restraints
3 Oncolytic Virus Therapy Market by Company
  1. 3.1 Global Oncolytic Virus Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Oncolytic Virus Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Oncolytic Virus Therapy Company Ranking (2024-2026)
  4. 3.4 Global Oncolytic Virus Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Oncolytic Virus Therapy Company Product Type and Application
  6. 3.6 Global Oncolytic Virus Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oncolytic Virus Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oncolytic Virus Therapy Market by Type
  1. 4.1 Oncolytic Virus Therapy Type Introduction
  2. 4.1.1 HSV-based Oncolytic Viruses
  3. 4.1.2 Adenoviruses-based Oncolytic Viruses
  4. 4.1.3 Vaccinia Virus-based Oncolytic Viruses
  5. 4.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
  6. 4.1.5 Newcastle Disease Virus-based Oncolytic Viruses
  7. 4.2 Global Oncolytic Virus Therapy Sales Value by Type
  8. 4.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oncolytic Virus Therapy Sales Value by Type (2021-2032)
  10. 4.2.3 Global Oncolytic Virus Therapy Sales Value Share by Type (2021-2032)
5 Oncolytic Virus Therapy Market by Application
  1. 5.1 Oncolytic Virus Therapy Application Introduction
  2. 5.1.1 Melanoma
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Ovarian Cancer
  6. 5.1.5 Others
  7. 5.2 Global Oncolytic Virus Therapy Sales Value by Application
  8. 5.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Oncolytic Virus Therapy Sales Value by Application (2021-2032)
  10. 5.2.3 Global Oncolytic Virus Therapy Sales Value Share by Application (2021-2032)
6 Oncolytic Virus Therapy Regional Value Analysis
  1. 6.1 Global Oncolytic Virus Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncolytic Virus Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oncolytic Virus Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oncolytic Virus Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncolytic Virus Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Oncolytic Virus Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oncolytic Virus Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Oncolytic Virus Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oncolytic Virus Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oncolytic Virus Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oncolytic Virus Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Oncolytic Virus Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oncolytic Virus Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oncolytic Virus Therapy Sales Value Share by Country, 2025 VS 2032
7 Oncolytic Virus Therapy Country-level Value Analysis
  1. 7.1 Global Oncolytic Virus Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncolytic Virus Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oncolytic Virus Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oncolytic Virus Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oncolytic Virus Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oncolytic Virus Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oncolytic Virus Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Oncolytics Biotech
  8. 8.2.1 Oncolytics Biotech Company Information
  9. 8.2.2 Oncolytics Biotech Business Overview
  10. 8.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
  12. 8.2.5 Oncolytics Biotech Recent Developments
  13. 8.3 Viralytics
  14. 8.3.1 Viralytics Company Information
  15. 8.3.2 Viralytics Business Overview
  16. 8.3.3 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
  18. 8.3.5 Viralytics Recent Developments
  19. 8.4 Transgene SA
  20. 8.4.1 Transgene SA Company Information
  21. 8.4.2 Transgene SA Business Overview
  22. 8.4.3 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
  24. 8.4.5 Transgene SA Recent Developments
  25. 8.5 Oncolys BioPharma
  26. 8.5.1 Oncolys BioPharma Company Information
  27. 8.5.2 Oncolys BioPharma Business Overview
  28. 8.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
  30. 8.5.5 Oncolys BioPharma Recent Developments
  31. 8.6 Targovax
  32. 8.6.1 Targovax Company Information
  33. 8.6.2 Targovax Business Overview
  34. 8.6.3 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
  36. 8.6.5 Targovax Recent Developments
  37. 8.7 PsiOxus Therapeutics
  38. 8.7.1 PsiOxus Therapeutics Company Information
  39. 8.7.2 PsiOxus Therapeutics Business Overview
  40. 8.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
  42. 8.7.5 PsiOxus Therapeutics Recent Developments
  43. 8.8 SillaJen Biotherapeutics
  44. 8.8.1 SillaJen Biotherapeutics Company Information
  45. 8.8.2 SillaJen Biotherapeutics Business Overview
  46. 8.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
  48. 8.8.5 SillaJen Biotherapeutics Recent Developments
  49. 8.9 Sorrento Therapeutics
  50. 8.9.1 Sorrento Therapeutics Company Information
  51. 8.9.2 Sorrento Therapeutics Business Overview
  52. 8.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
  54. 8.9.5 Sorrento Therapeutics Recent Developments
  55. 8.10 Lokon Pharma
  56. 8.10.1 Lokon Pharma Company Information
  57. 8.10.2 Lokon Pharma Business Overview
  58. 8.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
  60. 8.10.5 Lokon Pharma Recent Developments
  61. 8.11 Genelux Corporation
  62. 8.11.1 Genelux Corporation Company Information
  63. 8.11.2 Genelux Corporation Business Overview
  64. 8.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
  66. 8.11.5 Genelux Corporation Recent Developments
  67. 8.12 Vyriad
  68. 8.12.1 Vyriad Company Information
  69. 8.12.2 Vyriad Business Overview
  70. 8.12.3 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
  72. 8.12.5 Vyriad Recent Developments
  73. 8.13 TILT Biotherapeutics
  74. 8.13.1 TILT Biotherapeutics Company Information
  75. 8.13.2 TILT Biotherapeutics Business Overview
  76. 8.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
  78. 8.13.5 TILT Biotherapeutics Recent Developments
  79. 8.14 Cold Genesys
  80. 8.14.1 Cold Genesys Company Information
  81. 8.14.2 Cold Genesys Business Overview
  82. 8.14.3 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
  84. 8.14.5 Cold Genesys Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst